2 February 2017. KEI Europe, along with a coalition of groups, called upon the European Commission to reframe Horizon 2020 to explore alternative models of innovation that delinked the cost of R&D from the price of medicines.
January 2017. The joint submission to the Horizon 2020 consultation established six key recommendations that the European Commission should consider during their review process, including increased public investment in biomedical R&D funding, mandates on open data, and increased transparency.